Life Science Investing Ichnos Glenmark Innovation and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody 10 July
Life Science Investing AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody 10 July
